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lution of both measurable and evalu-
able disease needs to be taken into
account for future response definition.4
This also holds partly true for non-
evaluable MPM disease (like pleural
effusion or ascites) because, for objec-
tive complete tumor response, non-
evaluable MPM disease needs to be
completely absent. In MPM patients
with nonevaluable disease only where
no complete response is present, no
other MPM disease status can be as-
sessed.
As a suggestion, therefore, and
in expectation of possible newer eval-
uation tools for MPM,2 we would like
to propose the authors to provide cli-
nicians with a complete practical
guide on how to make radiologic mea-
surements and evaluations of all pos-
sible MPM cases, presenting mostly
with measurable, sometimes non-measur-
able, and occasionally with evaluable-only
pleural disease.
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In Reply:
We fully agree with Nackaerts et
al. that there are significant radio-
graphic challenges encountered when
measuring thoracic mesothelioma tu-
mors. As pointed out, mesothelioma is
not always measurable by computed
tomography (CT), magnetic resonance
imaging, or positron emission tomog-
raphy (PET) scans, and the classifica-
tion of “nonmeasurable but evaluable”
is a common conundrum. However,
given our limitations with cost, tech-
nology availability, and consistency in
radiographic measurements, the stan-
dard of care in cooperative group trials
is to measure thoracic mesothelioma
tumors with serial CT scans. Modified
RECIST criteria by Byrne and Nowak1
is the preferred method of evaluating pleu-
ral tumors on CT scans as pleural disease
measurements, using the short-axis rather
than the long-axis diameter, appear to cor-
relate better with clinical outcome.
Given the rare incidence of mesothe-
lioma and occasional confusion on
how to measure pleural rinds, the in-
tent of our recent publication2 was to
serve as a practical guide (a step-by-
step manual) to enhance consistency in
disease measure-ments for the South-
west Oncology Group institutions.
We concur with Nackaerts et al.
that our current measurement practice is
not optimal, and future studies of tech-
nology are vital to develop better and
more consistent measurements. In our
recent publication, we did not intend to
write a review on the different imaging
modalities of measuring mesothelioma,
which was clearly summarized in the
recent publication by Nowak et al.3 The
dilemma of measuring the “nonmeasur-
able but evaluable” mesothelioma
tumors is that there is currently no tech-
nology that has been validated or con-
sistently accurate. The labor-intensive
strategy of area measurements rather
than linear measurements would be im-
practical for a cooperative group to un-
dertake, as not all investigators would
have the resources, time, or expertise to
conduct this study. While fluorodeoxy-
glucose PET and PET-CT scans are
gaining popularity in imaging mesothe-
lioma, and does show some promise,
there are multiple factors that cause
standardized uptake value measure-
ments to vary from the initial baseline
study to subsequent serial studies; and
there is neither consensus nor validation
of response criteria for mesothelioma.
Some studies4–6 have previously re-
ported a correlation to clinical outcome
using either a metabolic response by
measuring maximum standardized up-
take values or total glycolytic volume;
however, these trials are small in num-
ber and other studies7,8 have reported
conflicting results. It is clear that addi-
tional prospective trials with radio-
graphic correlates are needed to validate
and develop new strategies based on our
current technical capabilities; we hope
that future research, perhaps new novel
PET tracers, will overcome the com-
plexity of measuring this nonspherical
tumor.
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How Should We Use
Bevacizumab in Patients
with Non-small Cell
Lung Cancer?
To the Editor:
The first phase III study of bevaci-
zumab in combination with chemotherapy
in patients with nonsquamous non-small
cell lung cancer (E4599) was conducted in
the United States, and both progression-
free survival (PFS) and overall survival
(OS) were significantly improved in the
bevacizumab arm1: however, in the sec-
ond phase III study (AVAiL) conducted in
the European Union, there was no signif-
icant difference in OS.2
When clinicians make a treatment
decision, there are three important points
to be considered: whether it prolongs OS,
whether it improves patients’ quality of
life, and how much it costs. Regarding
bevacizumab, the cost is high, and its
toxicity could compromise quality of life
and sometimes lead to serious conditions,
such as pulmonary hemorrhage and
thromboembolism. Therefore, OS im-
provement is necessary by using bevaci-
zumab; however, only one phase III
study has shown a survival advantage of
bevacizumab as mentioned above. Con-
sequently, skeptical oncologists do not
use bevacizumab for non-small cell lung
cancer patients even if they are free from
contraindications.
Table 1 summarizes the results of
three randomized studies of bevacizumab,
E4599,1 AVAiL,2 and a Japanese phase II
study (JO19907).3 As shown from the im-
proved response rate and PFS, bevaci-
zumab has reproducibly demonstrated
a strong antitumor effect throughout the
studies; however, only the E4599 study
demonstrated improved OS. How could we
use this potent drug appropriately?
Broglio and Berry4 addressed the
importance of survival postprogression
(SPP) and pointed out that lack of statis-
tical significance in OS does not necessar-
ily imply lack of improvement in OS,
especially when SPP is longer than 12
months. Despite the recent development
of efficient second- or third-line chemo-
therapy, SPP longer than 12 months is not
so common, except in patients with acti-
vating epidermal growth factor receptor
(EGFR) mutations. It seems quite reason-
able to assume that more than 30% of
included patients (East-Asian, nonsqua-
mous) had EGFR mutations and would
have received EGFR-tyrosine kinase in-
hibitor when disease progressed in each
arm, and the marked improvement of OS
in those patients might have negated the
significant difference in PFS in the
JO19907 study.
Collectively, bevacizumab in com-
bination with chemotherapy may be more
recommendable for patients with wild-
type EGFR than patients with EGFR mu-
tations in the current situation. As for
patients with EGFR mutants, the recently
published BeTa study,5 a randomized
phase III study comparing second-line er-
lotinib with or without bevacizumab, may
be useful. In this study, PFS doubled (3.4
versus 1.7 months, hazard ratio [HR]:
0.62), but OS was almost identical (9.3
versus 9.2 months, HR: 0.97). Interest-
ingly, the improvement of OS was more
prominent in EGFR mutants (HR: 0.44)
than EGFR wild-type (HR: 1.11) in sub-
group analysis. As the authors mentioned,
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TABLE 1. Randomized Studies of First-Line Bevacizumab in Combination with
Chemotherapy in NSCLC
E4599 AVAiL JO19907
Bev — 15 mg — 7.5 mg 15 mg — 15 mg
N 444 434 347 345 351 59 121
RR (%) 15 35 20 34 30 31 61
PFS (mo) 4.5 6.2 HR 6.1 6.7 6.5 HR 5.9 6.3 HR
0.66 0.75 (7.5 mg) 0.61
0.82 (15 mg)
OS (mo) 10.3 12.3 HR 13.7 14.1 14.5 HR 23.4 22.8 HR
0.79 0.94 (7.5 mg) 0.99
0.97 (15 mg)
NSCLC, non-small cell lung cancer; RR, response rate; PFS, progression-free survival; OS, overall survival; HR,
hazard ratio.
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